Maxalt

Rizatriptan, the active ingredient in Maxalt, is a Triptan presented as an oral tablet for oral administration. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients who require rapid symptom relief and can be used at the first sign of headache. GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across multiple regions. We adhere to stringent import standards.

Rizatriptan, a Triptan acting on serotonin receptors, is used for migraine management.

Migraine with aura: provides rapid relief of headache and associated symptoms. Migraine without aura: aborts attacks and reduces need for additional medication. Acute migraine episodes: can be taken at the first sign of headache to stop progression. Adults only: recommended for patients 18 years and older. Patients with contraindications to ergotamines: offers an alternative mechanism of action. Rapid onset: typically begins working within 30 minutes after ingestion. Improves functional ability: enables patients to resume normal activities sooner.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or toes - Nausea or abdominal pain - Dizziness or light‑headedness - Dry mouth - Fatigue

Serious or Rare Side Effects: - Serotonin syndrome, especially with serotonergic drugs - Cardiac ischemia or arrhythmia in susceptible patients - Severe allergic reaction (anaphylaxis) - Persistent visual disturbances - Severe hypertension - Pulmonary edema

Before prescribing Rizatriptan, clinicians should evaluate patient‑specific risk factors and comorbidities.

Assess cardiovascular risk: review history of coronary artery disease, hypertension, or stroke. Avoid in uncontrolled hypertension: ensure blood pressure is well‑controlled before use. Screen for drug interactions: check concomitant serotonergic agents that may increase serotonin syndrome risk. Pregnancy and lactation: consider limited safety data and weigh benefits against potential risks. Store at ambient temperature: keep tablets below 25°C in the original container, protected from moisture and light.

Rizatriptan can interact with several medication classes; careful review is essential.

Major Interactions (Avoid): - MAO inhibitors: combined use may precipitate serotonin syndrome. - Other triptans or ergotamine derivatives: additive vasoconstriction risk. - SSRIs, SNRIs, or other serotonergic agents: increased potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise rizatriptan plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effectiveness. - Certain antihypertensives: monitor blood pressure response.